GENE ONLINE|News &
Opinion
Blog

2021-05-05| Asia-Pacific

Singapore’s HMI Group Finds Global Partner to Improve Healthcare Delivery in Southeast Asia

by Rajaneesh K. Gopinath
Share To

Siemens Healthineers is a global medical technology company headquartered in Erlangen, Germany. Recently, the company has been actively forging large-scale collaborations with healthcare providers both locally and worldwide, including the USA, Canada, and Saudi Arabia. Now it has also added Southeast Asia to this list, initiating a first-of-its-kind partnership in the region.

On April 28th, Siemens Healthineers entered a 5-year strategic alliance worth $23.9 million (SGD 32 million) with Singapore’s Health Management International (HMI Group) to advance healthcare in Southeast Asia. This Value Partnership, as they call them, enables partners to optimize business processes, expand capabilities, and advance innovation.

“At Siemens Healthineers, we understand the challenges that healthcare providers face in meeting the demand of providing quality healthcare. We are delighted to have signed this strategic partnership with HMI Group, which is first such for us in Southeast Asia,” said Mr. Fabrice Leguet, Managing Director and Head of Siemens Healthineers, Southeast Asia.

“We will not only provide our innovative technology and digital solutions, but also support HMI Group to create value through enhanced training programs and provide healthcare consulting to further develop Centres of Excellence (CoEs) in the areas of cancer, neuroscience, and cardiovascular. This will further position HMI Group as a leading quality healthcare provider in the region,” he added.

Quest for Healthcare Innovation

HMI Group is a leading regional private healthcare services provider that is further expanding across Singapore and Malaysia. The company is part of the Enterprise Singapore (ESG)’s 12-18 months program called Scale-up SG. The company has already shown immense progress in digital transformation and community engagement to accelerate growth.

“This strategic partnership will enable HMI Group’s medical facilities to improve patient care by serving as flagship reference sites for Siemens Healthineers in Southeast Asia,” said Ms. Chin Wei Jia, Group CEO of HMI Group. “As the care of our patients is at the center of everything that we do, our partnership will accelerate the adoption of connected health, thereby providing faster access to care, while building telehealth and predictive analytics capabilities at scale, all of which will go a long way in enhancing our patients’ journey towards a healthier outcome.”

Non-communicable diseases such as cancer, cardiovascular disorders, and diabetes account for 62% of all deaths in Southeast Asia. Among Singapore, Malaysia, and Indonesia, this number increases to 74%. HMI Group aims to transform healthcare by boosting the adoption of digital health, big data, and precision diagnosis. With the latest deal, it would focus further on bolstering healthcare facilities, digitalization, and develop local talent.

Related Article: CSL Funds Four Australian Research Programs with Research Acceleration Initiative partnership

 

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Taiwanese Hospitals Make Strong Showing in “World’s Best Hospitals” Ranking
2024-03-12
AbbVie Boosts Global Manufacturing with $223 Million Expansion in Singapore
2024-01-29
The Gates Foundation Boosts Global Health Innovations with Record $8.6 Billion Budget
2024-01-18
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
Pharmacogenomics in Asia-Pacific: Nalagenetics CEO Levana Sani Offers Insights and Strategies
2024-04-17
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top